Therapies targeting hematopoietic stem cell residing in the bone marrow

ImmuneAGE Bio is pioneering a drug discovery platform focused on the rejuvenation of the immune system, specifically targeting hematopoietic stem cells (HSCs) from the bone marrow. Their innovative "StemSupply" platform allows for an unprecedented expansion of HSCs by over 1,000 times, which significantly enhances the efficacy of bone marrow transplants and enables high-throughput drug screening on human HSCs. This technology aims to create a future where individuals have access to a reliable bone marrow donor pool, improving resilience against pandemics and cancer, ultimately leading to a reduction in hospital stays and an increase in healthy, productive years.

In addition to the StemSupply platform, ImmuneAGE Bio has developed the AgeScreen: Geroscience Drug Discovery Engine, which utilizes a series of assays to identify new molecules that regulate cellular aging, with a particular focus on immune cell aging. This dual rejuvenation approach not only addresses the aging of the immune system but also opens avenues for expanding therapeutic applications across various aging-related pathologies. Through these technologies, ImmuneAGE Bio is positioned to redefine longevity and health in the context of modern medicine.

United States

ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation.

ImmuneAGE Bio

Company Details